NEW YORK, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq:DNLI), a biopharmaceutical company focused on the discovery and development of therapies for patients with neurodegenerative disease, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9f884ad2-04de-4bbe-a467-faad9d522506
Denali Therapeutics is committed to developing therapies for neurodegeneration, one of the most significant unmet medical needs of our time. Denali Therapeutics relies on its core principles of identifying and selecting targets based on validated genetic drivers of neurodegeneration, developing medicines that effectively cross the blood-brain barrier and target the brain, and developing and using biomarkers for better patient selection and demonstration of target and pathway engagement of their product candidates in order to succeed in a field that has seen limited progress in the past several decades.
“Neurodegenerative diseases represent one of the most significant medical challenges facing us today, impacting millions of people including our own families and friends. Our goal is to defeat degeneration,” said Ryan J. Watts, Ph.D. co-founder and CEO of Denali Therapeutics. “We are grateful for the investors who have joined us on this journey and share our vision that the science is breaking open, and the time is right to discover and develop effective medicines for patients.”
“With a team of experienced and passionately dedicated scientists and drug developers, Denali Therapeutics is committed to developing innovative therapies for a field with severely unmet medical needs,” said Nelson Griggs, President of the Nasdaq Stock Exchange. “As the largest capital raise by a biotechnology company since June 2015 as well as largest raise in healthcare deals in 2017, we are proud to welcome Denali Therapeutics to our family of the world’s most prestigious companies as they continue to make strides in the neurodegeneration field.”
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com
|MEDIA RELATIONS CONTACT: || |
- NDAQG -